Myocardial protection from ischemia-reperfusion injury post coronary revascularization

References

• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498-504
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121(7):e46-e215
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014;129(3):e28-e292
   PubMed Web of Science ®Google Scholar
• Majidi M, Kosinski AS, Al-Khatib SM, et al. Reperfusion ventricular arrhythmia ‘bursts’ predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction. Eur Heart J 2009;30(7):757-64
   PubMed Web of Science ®Google Scholar
• Costa MA, Carere RG, Lichtenstein SV, et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation 2001;104(22):2689-93
   PubMed Web of Science ®Google Scholar
• Majidi M, Kosinski AS, Al-Khatib SM, et al. Implications of ventricular arrhythmia “bursts” with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: A biosignature of direct myocellular injury “downstream of downstream”. Eur Heart J Acute Cardiovasc Care 2014;4(1):51-9
   Google Scholar
• Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: Preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol 2011;301(5):H1723-41
   PubMed Web of Science ®Google Scholar
• Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357(11):1121-35
   PubMed Web of Science ®Google Scholar
• Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31(2):241-51
   PubMed Web of Science ®Google Scholar
• Roe MT, Mahaffey KW, Kilaru R, et al. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J 2004;25(4):313-21
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003;42(8):1406-11
   PubMed Web of Science ®Google Scholar
• Domanski MJ, Mahaffey K, Hasselblad V, et al. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA 2011;305(6):585-91
   PubMed Web of Science ®Google Scholar
• Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346(8):549-56
   PubMed Web of Science ®Google Scholar
• American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005;112(24 Suppl):IV1-203
   PubMed Web of Science ®Google Scholar
• Gotberg M, Olivecrona GK, Koul S, et al. A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction. Circ Cardiovasc Interv 2010;3(5):400-7
   PubMed Web of Science ®Google Scholar
• Erlinge D, Gotberg M, Lang I, et al. Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol 2014;63(18):1857-65
   PubMed Web of Science ®Google Scholar
• Abbate A, Kontos MC, Biondi-Zoccai GG. No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction. Eur Heart J 2008;29(15):1795-7
   PubMed Web of Science ®Google Scholar
• Jaffe R, Dick A, Strauss BH. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. JACC Cardiovasc Interv 2010;3(7):695-704
   PubMed Web of Science ®Google Scholar
• Niccoli G, Marino M, Spaziani C, Crea F. Prevention and treatment of no-reflow. Acute Card Care 2010;12(3):81-91
   PubMedGoogle Scholar
• Wang QD, Pernow J, Sjoquist PO, Ryden L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res 2002;55(1):25-37
   PubMed Web of Science ®Google Scholar
• Steenbergen C, Perlman ME, London RE, Murphy E. Mechanism of preconditioning. Ionic alterations. Circ Res 1993;72(1):112-25
   PubMed Web of Science ®Google Scholar
• Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol 2010;106(3):360-8
   PubMed Web of Science ®Google Scholar
• Li L, Luo W, Huang L, et al. Remote perconditioning reduces myocardial injury in adult valve replacement: A randomized controlled trial. J Surg Res 2010;164(1):e21-6
   PubMed Web of Science ®Google Scholar
• Thielmann M, Kottenberg E, Boengler K, et al. Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 2010;105(5):657-64
   PubMed Web of Science ®Google Scholar
• Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005;112(14):2143-8
   PubMed Web of Science ®Google Scholar
• Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285(2):H579-88
   PubMed Web of Science ®Google Scholar
• Xue F, Yang X, Zhang B, et al. Postconditioning the human heart in percutaneous coronary intervention. Clin Cardiol 2010;33(7):439-44
   PubMed Web of Science ®Google Scholar
• Lonborg J, Kelbaek H, Vejlstrup N, et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interv 2010;3(1):34-41
   PubMed Web of Science ®Google Scholar
• Sorensson P, Saleh N, Bouvier F, et al. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart 2010;96(21):1710-15
   PubMed Web of Science ®Google Scholar
• Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995;146(1):3-15
   PubMed Web of Science ®Google Scholar
• Eefting F, Rensing B, Wigman J, et al. Role of apoptosis in reperfusion injury. Cardiovasc Res 2004;61(3):414-26
   PubMed Web of Science ®Google Scholar
• Mocanu MM, Baxter GF, Yellon DM. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol 2000;130(2):197-200
   PubMed Web of Science ®Google Scholar
• Frolich O, Karmazyn M. The Na-H exchanger revisited: an update on Na-H exchange regulation and the role of the exchanger in hypertension and cardiac function in health and disease. Cardiovasc Res 1997;36(2):138-48
   PubMed Web of Science ®Google Scholar
• Avkiran M. Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia. Am J Cardiol 1999;83(10A):10G-7G
   PubMed Web of Science ®Google Scholar
• Scholz W, Albus U, Counillon L, et al. Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc Res 1995;29(2):260-8
   PubMed Web of Science ®Google Scholar
• Theroux P, Chaitman BR, Danchin N, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation 2000;102(25):3032-8
   PubMed Web of Science ®Google Scholar
• Mentzer RMJr, Bartels C, Bolli R, et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg 2008;85(4):1261-70
   PubMed Web of Science ®Google Scholar
• Forman MB, Velasco CE, Jackson EK. Adenosine attenuates reperfusion injury following regional myocardial ischaemia. Cardiovasc Res 1993;27(1):9-17
   PubMed Web of Science ®Google Scholar
• Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation 1992;85(3):893-904
   PubMed Web of Science ®Google Scholar
• Pitarys CJII, Virmani R, Vildibill HDJr, et al. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 1991;83(1):237-47
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34(6):1711-20
   PubMed Web of Science ®Google Scholar
• Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45(11):1775-80
   PubMed Web of Science ®Google Scholar
• Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006;27(20):2400-5
   PubMed Web of Science ®Google Scholar
• Fokkema ML, Vlaar PJ, Vogelzang M, et al. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv 2009;2(4):323-9
   PubMed Web of Science ®Google Scholar
• Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J 2011;32(7):867-77
   PubMed Web of Science ®Google Scholar
• Jin Z, Duan W, Chen M, et al. The myocardial protective effects of adenosine pretreatment in children undergoing cardiac surgery: a randomized controlled clinical trial. Eur J Cardiothorac Surg 2011;39(5):e90-6
   PubMed Web of Science ®Google Scholar
• Chen Q, Camara AK, Stowe DF, et al. Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion. Am J Physiol Cell Physiol 2007;292(1):C137-47
   PubMed Web of Science ®Google Scholar
• Bernardi P, Petronilli V. The permeability transition pore as a mitochondrial calcium release channel: a critical appraisal. J Bioenerg Biomembr 1996;28(2):131-8
   PubMed Web of Science ®Google Scholar
• Javadov S, Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem 2007;20(1-4):1-22
   PubMed Web of Science ®Google Scholar
• Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307(Pt 1):93-8
   PubMedGoogle Scholar
• Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002;55(3):534-43
   PubMed Web of Science ®Google Scholar
• Oka N, Wang L, Mi W, et al. Cyclosporine A prevents apoptosis-related mitochondrial dysfunction after neonatal cardioplegic arrest. J Thorac Cardiovasc Surg 2008;135(1):123-30; 130 e121-122
   PubMed Web of Science ®Google Scholar
• Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359(5):473-81
   PubMed Web of Science ®Google Scholar
• Kukreja RC. Sildenafil and cardioprotection. Curr Pharm Des 2013;19(39):6842-7
   PubMed Web of Science ®Google Scholar
• Szabo G, Radovits T, Veres G, et al. Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass. Eur J Cardiothorac Surg 2009;36(4):657-64
   PubMed Web of Science ®Google Scholar
• Das A, Ockaili R, Salloum F, Kukreja RC. Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol 2004;286(4):H1455-60
   PubMed Web of Science ®Google Scholar
• Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 2002;283(3):H1263-9
   PubMed Web of Science ®Google Scholar
• Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003;92(6):595-7
   PubMed Web of Science ®Google Scholar
• Krenzelok EP. Sildenafil: clinical toxicology profile. J Toxicol Clin Toxicol 2000;38(6):645-51
   PubMed Web of Science ®Google Scholar
• Raja SG. Cardioprotection with sildenafil: implications for clinical practice. Curr Med Chem 2006;13(26):3155-64
   PubMed Web of Science ®Google Scholar
• Das A, Salloum FN, Xi L, et al. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 2009;296(5):H1236-43
   PubMed Web of Science ®Google Scholar
• Gori T, Sicuro S, Dragoni S, et al. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005;111(6):742-6
   PubMed Web of Science ®Google Scholar
• Ali A, Binder A, Mohmand A, et al. The safety of preoperative vardenafil in patients undergoing coronary artery bypass graft surgery. J Cardiovasc Pharmacol 2013;62(1):106-9
   PubMed Web of Science ®Google Scholar
• Jiang F, Yang J, Zhang L, et al. Rosuvastatin reduces ischemia-reperfusion injury in patients with acute coronary syndrome treated with percutaneous coronary intervention. Clin Cardiol 2014;37(9):530-5
   PubMed Web of Science ®Google Scholar
• Melly L, Boccardo S, Eckstein F, et al. Cell and gene therapy approaches for cardiac vascularization. Cells 2012;1(4):961-75
   Google Scholar
• Lipsic E, Schoemaker RG, van der Meer P, et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48(11):2161-7
   PubMed Web of Science ®Google Scholar
• Tada H, Kagaya Y, Takeda M, et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res 2006;71(3):466-77
   PubMed Web of Science ®Google Scholar
• Westenbrink BD, Lipsic E, van der Meer P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007;28(16):2018-27
   PubMed Web of Science ®Google Scholar
• Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112(7):999-1007
   PubMed Web of Science ®Google Scholar
• Voors AA, Belonje AM, Zijlstra F, et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010;31(21):2593-600
   PubMed Web of Science ®Google Scholar
• Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011;305(18):1863-72
   PubMed Web of Science ®Google Scholar
• Melloni C, Rao SV, Povsic TJ, et al. Design and rationale of the reduction of infarct expansion and ventricular remodeling with erythropoietin after large myocardial infarction (REVEAL) trial. Am Heart J 2010;160(5):795-803 e792
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Roe M, Aylward P, et al. Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. Eur Heart J 2014;35(37):2516-23
   PubMed Web of Science ®Google Scholar
• Weman SM, Karhunen PJ, Penttila A, et al. Reperfusion injury associated with one-fourth of deaths after coronary artery bypass grafting. Ann Thorac Surg 2000;70(3):807-12
   PubMed Web of Science ®Google Scholar
• Walsh SR, Tang TY, Kullar P, et al. Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials. Eur J Cardiothorac Surg 2008;34(5):985-94
   PubMed Web of Science ®Google Scholar
• Lee HT, LaFaro RJ, Reed GE. Pretreatment of human myocardium with adenosine during open heart surgery. J Card Surg 1995;10(6):665-76
   PubMed Web of Science ®Google Scholar
• Mangano DT. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA 1997;277(4):325-32
   PubMedGoogle Scholar
• Wei M, Wang X, Kuukasjarvi P, et al. Bradykinin preconditioning in coronary artery bypass grafting. Ann Thorac Surg 2004;78(2):492-7
   PubMed Web of Science ®Google Scholar
• Wang X, Wei M, Kuukasjarvi P, et al. Novel pharmacological preconditioning with diazoxide attenuates myocardial stunning in coronary artery bypass grafting. Eur J Cardiothorac Surg 2003;24(6):967-73
   PubMed Web of Science ®Google Scholar
• Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 2004;291(19):2319-27
   PubMed Web of Science ®Google Scholar
• Yu CH, Beattie WS. The effects of volatile anesthetics on cardiac ischemic complications and mortality in CABG: a meta-analysis. Can J Anaesth 2006;53(9):906-18
   PubMed Web of Science ®Google Scholar
• Tardif JC, Carrier M, Kandzari DE, et al. Effects of pyridoxal-5’-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. J Thorac Cardiovasc Surg 2007;133(6):1604-11
   PubMed Web of Science ®Google Scholar
• Alexander JH, Emery RWJr, Carrier M, et al. Efficacy and safety of pyridoxal 5’-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. JAMA 2008;299(15):1777-87
   PubMed Web of Science ®Google Scholar
• Smith PK, Carrier M, Chen JC, et al. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. Ann Thorac Surg 2006;82(3):781-8
   PubMed Web of Science ®Google Scholar
• Smith PK, Shernan SK, Chen JC, et al. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg 2011;142(1):89-98
   PubMed Web of Science ®Google Scholar
• Testa L, Van Gaal WJ, Bhindi R, et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg 2008;136(4):884-93
   PubMed Web of Science ®Google Scholar
• Bendall JK, Douglas G, McNeill E, et al. Tetrahydrobiopterin in cardiovascular health and disease. Antioxid Redox Signal 2014;20(18):3040-77
   PubMed Web of Science ®Google Scholar
• Szabo G, Seres L, Soos P, et al. Tetrahydrobiopterin improves cardiac and pulmonary function after cardiopulmonary bypass. Eur J Cardiothorac Surg 2011;40(3):695-700
   PubMed Web of Science ®Google Scholar
• Korkmaz S, Radovits T, Barnucz E, et al. Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Circulation 2009;120(8):677-86
   PubMed Web of Science ®Google Scholar
• Radovits T, Korkmaz S, Miesel-Groschel C, et al. Pre-conditioning with the soluble guanylate cyclase activator cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. Eur J Cardiothorac Surg 2011;39(2):248-55
   PubMed Web of Science ®Google Scholar
• Asanuma H, Sanada S, Asakura M, et al. Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO. Hypertens Res 2014;37(8):716-23
   PubMed Web of Science ®Google Scholar
• Przyklenk K. Efficacy of cardioprotective ‘conditioning’ strategies in aging and diabetic cohorts: the co-morbidity conundrum. Drugs Aging 2011;28(5):331-43
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Alderman EL, Sheffield LT, et al. Use of survival analysis to determine the clinical significance of new Q waves after coronary bypass surgery. Circulation 1983;67(2):302-9
   PubMed Web of Science ®Google Scholar
• Kugelmass AD, Cohen DJ, Moscucci M, et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 1994;74(8):748-54
   PubMed Web of Science ®Google Scholar
• Abdelmeguid AE, Whitlow PL, Sapp SK, et al. Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation 1995;91(11):2733-41
   PubMed Web of Science ®Google Scholar
• Abdelmeguid AE, Topol EJ, Whitlow PL, et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94(7):1528-36
   PubMed Web of Science ®Google Scholar
• Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001;104(6):642-7
   PubMed Web of Science ®Google Scholar
• Brener SJ, Lytle BW, Schneider JP, et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002;40(11):1961-7
   PubMed Web of Science ®Google Scholar
• Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002;39(11):1738-44
   PubMed Web of Science ®Google Scholar
• Feldman DN, Minutello RM, Bergman G, et al. Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes. Am J Cardiol 2009;104(9):1210-15
   PubMed Web of Science ®Google Scholar
• Li XL, Li JJ, Guo YL, et al. Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention. J Clin Lipidol 2014;8(4):423-32
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Tzalamouras V, et al. Renoprotective effect of remote ischemic post-conditioning by intermittent balloon inflations in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2013;61(19):1949-55
   PubMed Web of Science ®Google Scholar